NASDAQ:EYPT EyePoint Pharmaceuticals (EYPT) Stock Forecast, Price & News $6.13 -0.28 (-4.37%) (As of 05/18/2023 ET) Add Compare Share Share Today's Range$5.79▼$6.7650-Day Range$2.28▼$9.0052-Week Range$2.19▼$11.44Volume1.14 million shsAverage Volume674,888 shsMarket Capitalization$210.26 millionP/E RatioN/ADividend YieldN/APrice Target$26.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media EyePoint Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside434.3% Upside$32.75 Price TargetShort InterestBearish14.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.58) to ($2.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector352nd out of 989 stocksAnalytical Instruments Industry9th out of 29 stocks 3.5 Analyst's Opinion Consensus RatingEyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.75, EyePoint Pharmaceuticals has a forecasted upside of 434.3% from its current price of $6.13.Amount of Analyst CoverageEyePoint Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.13% of the float of EyePoint Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in EyePoint Pharmaceuticals has recently decreased by 0.27%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEyePoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyePoint Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EYPT. Previous Next 3.2 News and Social Media Coverage News SentimentEyePoint Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for EyePoint Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest34 people have searched for EYPT on MarketBeat in the last 30 days. This is an increase of 580% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added EyePoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, EyePoint Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders11.88% of the stock of EyePoint Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.27% of the stock of EyePoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for EyePoint Pharmaceuticals are expected to grow in the coming year, from ($2.58) to ($2.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of EyePoint Pharmaceuticals is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of EyePoint Pharmaceuticals is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyePoint Pharmaceuticals has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About EyePoint Pharmaceuticals (NASDAQ:EYPT) StockEyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.Read More Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Stock News HeadlinesMay 18, 2023 | msn.comGuggenheim Maintains EyePoint Pharmaceuticals (EYPT) Buy RecommendationMay 14, 2023 | finance.yahoo.comShareholders in EyePoint Pharmaceuticals (NASDAQ:EYPT) have lost 72%, as stock drops 10% this past weekMay 18, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...May 12, 2023 | americanbankingnews.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Upgraded to Hold at StockNews.comMay 10, 2023 | americanbankingnews.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Expected to Earn FY2024 Earnings of ($2.32) Per ShareMay 9, 2023 | americanbankingnews.comEyePoint Pharmaceuticals, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.58) Per Share (NASDAQ:EYPT)May 5, 2023 | markets.businessinsider.comRobert W. Baird Remains a Buy on EyePoint Pharmaceuticals (EYPT)May 3, 2023 | msn.comEyePoint stock soars 20% after Q1 sees growth in Yutiq salesMay 18, 2023 | Behind the Markets (Ad)"Chilling War Games Show US Forces Crushed" – FOX NEWS=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>May 3, 2023 | finance.yahoo.comWhy EyePoint Pharmaceuticals Shares Are Shooting Higher TodayMay 3, 2023 | finance.yahoo.comEyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate DevelopmentsMay 3, 2023 | americanbankingnews.comShort Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Rises By 9.3%May 2, 2023 | markets.businessinsider.comHere's what Wall Street expects from EyePoint Pharmaceuticals's earnings reportMay 1, 2023 | americanbankingnews.comEyePoint Pharmaceuticals (EYPT) Set to Announce Earnings on WednesdayApril 26, 2023 | finance.yahoo.comEyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023April 26, 2023 | americanbankingnews.comStockNews.com Downgrades EyePoint Pharmaceuticals (NASDAQ:EYPT) to SellApril 23, 2023 | americanbankingnews.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Earns Outperform Rating from Analysts at Robert W. BairdApril 21, 2023 | markets.businessinsider.comEyePoint Pharmaceuticals (EYPT) Receives a Buy from Robert W. BairdApril 20, 2023 | finance.yahoo.comStrength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength?April 17, 2023 | finance.yahoo.comSubdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 84%March 31, 2023 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT)March 29, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)March 27, 2023 | finance.yahoo.comEyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMDMarch 20, 2023 | finance.yahoo.comEyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingMarch 9, 2023 | finance.yahoo.comDown -32.42% in 4 Weeks, Here's Why You Should You Buy the Dip in EyePoint Pharmaceuticals (EYPT)March 6, 2023 | finance.yahoo.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2022 Earnings Call TranscriptMarch 4, 2023 | finance.yahoo.comEyePoint Pharmaceuticals Full Year 2022 Earnings: EPS Misses ExpectationsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Company Calendar Last Earnings3/02/2023Today5/18/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYPT CUSIPN/A CIK1314102 Webeyepointpharma.com Phone(617) 926-5000Fax617-926-5050Employees122Year Founded1987Price Target and Rating Average Stock Price Forecast$32.75 High Stock Price Forecast$52.00 Low Stock Price Forecast$21.00 Forecasted Upside/Downside+277.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,250,000.00 Net Margins-257.44% Pretax Margin-257.44% Return on Equity-70.70% Return on Assets-41.45% Debt Debt-to-Equity Ratio0.37 Current Ratio5.36 Quick Ratio5.21 Sales & Book Value Annual Sales$41.40 million Price / Sales5.77 Cash FlowN/A Price / Cash FlowN/A Book Value$2.29 per share Price / Book3.04Miscellaneous Outstanding Shares34,300,000Free Float30,227,000Market Cap$239.07 million OptionableOptionable Beta1.12 Social Links Key ExecutivesNancy Sue LurkerChief Executive Officer & DirectorJay S. DukerPresident & Chief Operating OfficerGeorge O. ElstonCFO & Head-Corporate DevelopmentDario A. PaggiarinoChief Medical Officer & Senior Vice PresidentSaid SaimChief Technology OfficerKey CompetitorsBionano GenomicsNASDAQ:BNGOSeerNASDAQ:SEERAkoya BiosciencesNASDAQ:AKYAStandard BioToolsNASDAQ:LABCue HealthNASDAQ:HLTHView All CompetitorsInstitutional OwnershipGeode Capital Management LLCBought 28,651 shares on 5/16/2023Ownership: 1.404%Squarepoint Ops LLCBought 65,786 shares on 5/16/2023Ownership: 0.192%Two Sigma Advisers LPSold 8,100 shares on 5/15/2023Ownership: 0.227%Two Sigma Investments LPSold 21,277 shares on 5/15/2023Ownership: 0.159%Deutsche Bank AGBought 14,493 shares on 5/15/2023Ownership: 0.073%View All Institutional Transactions EYPT Stock - Frequently Asked Questions Should I buy or sell EyePoint Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYPT shares. View EYPT analyst ratings or view top-rated stocks. What is EyePoint Pharmaceuticals' stock price forecast for 2023? 4 equities research analysts have issued 1-year price targets for EyePoint Pharmaceuticals' stock. Their EYPT share price forecasts range from $21.00 to $52.00. On average, they anticipate the company's stock price to reach $32.75 in the next year. This suggests a possible upside of 369.9% from the stock's current price. View analysts price targets for EYPT or view top-rated stocks among Wall Street analysts. How have EYPT shares performed in 2023? EyePoint Pharmaceuticals' stock was trading at $3.50 at the beginning of 2023. Since then, EYPT stock has increased by 99.1% and is now trading at $6.97. View the best growth stocks for 2023 here. When is EyePoint Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our EYPT earnings forecast. How were EyePoint Pharmaceuticals' earnings last quarter? EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) released its quarterly earnings data on Thursday, March, 2nd. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.02. The business earned $10.53 million during the quarter, compared to analyst estimates of $9.71 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 70.70% and a negative net margin of 257.44%. When did EyePoint Pharmaceuticals' stock split? EyePoint Pharmaceuticals's stock reverse split before market open on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of EyePoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX). What is EyePoint Pharmaceuticals' stock symbol? EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT." Who are EyePoint Pharmaceuticals' major shareholders? EyePoint Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (16.85%), Suvretta Capital Management LLC (9.90%), BlackRock Inc. (4.44%), Geode Capital Management LLC (1.40%), Bank of America Corp DE (0.97%) and Essex Investment Management Co. LLC (0.69%). View institutional ownership trends. How do I buy shares of EyePoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is EyePoint Pharmaceuticals' stock price today? One share of EYPT stock can currently be purchased for approximately $6.97. How much money does EyePoint Pharmaceuticals make? EyePoint Pharmaceuticals (NASDAQ:EYPT) has a market capitalization of $239.07 million and generates $41.40 million in revenue each year. The company earns $-102,250,000.00 in net income (profit) each year or ($2.73) on an earnings per share basis. How many employees does EyePoint Pharmaceuticals have? The company employs 122 workers across the globe. How can I contact EyePoint Pharmaceuticals? EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The official website for the company is eyepointpharma.com. The company can be reached via phone at (617) 926-5000, via email at eyepoint@argotpartners.com, or via fax at 617-926-5050. This page (NASDAQ:EYPT) was last updated on 5/18/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.